Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Completed

Conditions studied: Melanoma

In brief

This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.

Key facts

Study ID

NCT03165409

Run by

Bristol-Myers Squibb

People needed

1828

Starts

2017-02-27

Expected to finish

2017-09-30

Last updated by the study team

2017-10-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with metastatic melanoma
• Initiated at least 1 treatment for metastatic melanoma after 2011
• Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date
• Patients who received at least 1 dose of study drug in CA209-067

Where it is running

• Bristol-Myers Squibb — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.